Literature DB >> 23804778

Prognostic value of perioperative near-infrared spectroscopy during neonatal and infant congenital heart surgery for adverse in-hospital clinical events.

Jannika Dodge-Khatami1, Urda Gottschalk, Christine Eulenburg, Ulrike Wendt, Clivia Schnegg, Marcus Rebel, Hermann Reichenspurner, Ali Dodge-Khatami.   

Abstract

BACKGROUND: Perioperative monitoring with multisite near-infrared spectroscopy (NIRS) for congenital cardiac surgery with cardiopulmonary bypass may aid in predicting adverse clinical outcomes.
METHODS: Forty-one consecutive neonates and infants undergoing bypass were monitored with right + left cerebral and renal NIRS. Near-infrared spectroscopy and lactate were measured at 20 time points, from baseline 1 day preoperatively, during bypass and modified ultrafiltration (MUF; 10 minutes), until 24 hours postoperatively. Adverse events were extracorporeal membrane oxygenation (ECMO)/death, prolonged intensive care unit (ICU) or length of hospital stay.
RESULTS: Perioperative mean renal NIRS remained higher than baseline (n = 41) as did cerebral NIRS in all undergoing biventricular repair. During bypass (n = 41), mean right and left cerebral NIRS were equal. During MUF, cerebral and renal NIRS values increased (P < .001). Cerebral NIRS and lactate inversely correlated during the first six postoperative hours. Extracorporeal membrane oxygenation /death occurred in four patients, correlating with cerebral and renal NIRS below 45% (P = .030) and 40% (P = .019) at anytime, respectively, and with mean lactate levels >9.3 mmol/L in the first postoperative 24 hours (P < .001). Among survivors, renal NIRS below 30% at any time predicted a longer ICU stay.
CONCLUSIONS: At bypass conclusion, 10 minutes of MUF does not adversely affect cerebral or renal NIRS. Left and right cerebral NIRS are equal, so that biparietal cerebral NIRS monitoring is probably not warranted. Perioperative cerebral and renal NIRS readings, respectively, below 45% and 40% correlate with ECMO/death and renal NIRS below 30% with prolonged ICU stay. Cerebral NIRS and lactate levels showed a strong inverse correlation during the first six postoperative hours.

Entities:  

Keywords:  cardiopulomonary bypass; congenital heart surgery; outcomes; pathophysiology

Year:  2012        PMID: 23804778     DOI: 10.1177/2150135111426298

Source DB:  PubMed          Journal:  World J Pediatr Congenit Heart Surg        ISSN: 2150-1351


  5 in total

1.  Antegrade cerebral perfusion at 25 °C for arch reconstruction in newborns and children preserves perioperative cerebral oxygenation and serum creatinine.

Authors:  Bhawna Gupta; Ali Dodge-Khatami; Juan Tucker; Mary B Taylor; Douglas Maposa; Miguel Urencio; Jorge D Salazar
Journal:  Transl Pediatr       Date:  2016-07

Review 2.  Recent innovations in perfusion and cardiopulmonary bypass for neonatal and infant cardiac surgery.

Authors:  David Sturmer; Claude Beaty; Sean Clingan; Eric Jenkins; Whitney Peters; Ming-Sing Si
Journal:  Transl Pediatr       Date:  2018-04

Review 3.  Renal Tissue Oxygenation Monitoring-An Opportunity to Improve Kidney Outcomes in the Vulnerable Neonatal Population.

Authors:  Matthew W Harer; Valerie Y Chock
Journal:  Front Pediatr       Date:  2020-05-14       Impact factor: 3.418

4.  Protecting brains and saving futures guidelines: A prospective, multicenter, and observational study on the use of telemedicine for neonatal neurocritical care in Brazil.

Authors:  Gabriel Fernando Todeschi Variane; Maurício Magalhães; Rafaela Fabri Rodrigues Pietrobom; Alexandre Netto; Daniela Pereira Rodrigues; Renato Gasperini; Guilherme Mendes Sant'Anna
Journal:  PLoS One       Date:  2022-01-12       Impact factor: 3.240

5.  Impact on Renal Function and Hospital Outcomes of an Individualized Management of Cardiopulmonary Bypass in Congenital Heart Surgery: A Pilot Study.

Authors:  Riccardo Giuseppe Abbasciano; Stiljan Hoxha; Dania Gaburro; Siliva Surdo; Tiziano Menon; Leonardo Gottin; Giuseppe Faggian; Giovanni Battista Luciani
Journal:  Pediatr Cardiol       Date:  2021-07-22       Impact factor: 1.655

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.